

Resource Summary Report

Generated by [RRID](#) on Sep 6, 2026

ANBL-6

RRID:CVCL_5425

Type: Cell Line

Proper Citation

RRID:CVCL_5425

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_5425

Proper Citation: RRID:CVCL_5425

Description: Cell line ANBL-6 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Plasma cell myeloma

Defining Citation: [PMID:8221668](#), [PMID:8943038](#), [PMID:10583232](#), [PMID:10936422](#), [PMID:11154231](#), [PMID:11157491](#), [PMID:16956823](#), [PMID:17692805](#), [PMID:18647998](#), [PMID:19344406](#), [PMID:21173094](#), [PMID:23992230](#), [PMID:24013424](#), [PMID:25015330](#), [PMID:25688540](#), [PMID:32123307](#)

Comments: Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck, Catherine., Characteristics: IL6 dependent., Characteristics: Produces Ig lambda., Population: Caucasian.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: ANBL-6

Synonyms: ANBL6

Cross References: ArrayExpress:E-TABM-1088, cancercellines:CVCL_5425, Cosmic:720790, Cosmic:1170891, Cosmic:2081377, Cosmic:2367285, IARC_TP53:28510, Millipore:SCC429, Wikidata:Q54749908

ID: CVCL_5425

Record Creation Time: 20220427T215219+0000

Record Last Update: 20260905T184639+0000

Ratings and Alerts

No rating or validation information has been found for ANBL-6.

No alerts have been found for ANBL-6.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Wu J, et al. (2026) Hi-C for genome-wide detection of enhancer-hijacking rearrangements in routine lymphoid cancer biopsies. *Cell genomics*, 6(5), 101166.

Fulciniti M, et al. (2026) ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3. *Blood cancer discovery*, 7(1), 129.

Li S, et al. (2025) Self-Assembling Multi-Antigen T Cell Hybridizers for Precision Immunotherapy of Multiple Myeloma. *Advanced healthcare materials*, e02156.

Singh RK, et al. (2024) Novel Anti-B-cell Maturation Antigen Alpha-Amanitin Antibody-drug Conjugate HDP-101 Shows Superior Activity to Belantamab Mafodotin and Enhanced Efficacy in Deletion 17p Myeloma Models. *Research square*.

Wadhwa A, et al. (2024) CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(5), 1009.

Yu Z, et al. (2022) Indirubin-3'-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma. *EBioMedicine*, 78, 103950.